ANGELEXO SCIENTIFIC CO., LTD – Trademark Portfolio

Entity Type: 99

ANGELEXO SCIENTIFIC CO., LTD holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 4 filings in this category. Currently, 4 trademarks are registered. Notable registered marks include EXOMAX, ANGELEXO, EXOPEDIA, and LITESTEPPER. The owner is based in HANGZHOU, ZHEJIANG.

SUITE 1308, BLOCK B,4083 JIANSHE 4TH RD.

XINJIE SCIENCE & TECHNOLOGY IND. PARK

HANGZHOU, ZHEJIANG XIAOSHAND , CN

4 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

ANGELEXO
ANGELEXO
Registered 2022
EXOMAX
EXOMAX
Registered 2022
EXOPEDIA
EXOPEDIA
Registered 2022

Trademark Classifications

ANGELEXO SCIENTIFIC CO., LTD's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (4 filings)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does ANGELEXO SCIENTIFIC CO., LTD have?

ANGELEXO SCIENTIFIC CO., LTD has 4 U.S. trademarks filed with the USPTO. Of these, 4 registered.

What trademark classes does ANGELEXO SCIENTIFIC CO., LTD file in?

ANGELEXO SCIENTIFIC CO., LTD files trademarks across 1 Nice Classification class. The most active classes are Class 10 (Medical Apparatus). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are ANGELEXO SCIENTIFIC CO., LTD's most well-known trademarks?

ANGELEXO SCIENTIFIC CO., LTD's registered trademark portfolio includes well-known marks such as EXOMAX, ANGELEXO, EXOPEDIA, and LITESTEPPER. These are among 4 currently registered trademarks in the portfolio.

What is ANGELEXO SCIENTIFIC CO., LTD's trademark registration success rate?

ANGELEXO SCIENTIFIC CO., LTD has a 100% trademark registration rate, with 4 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.